SAB Biotherapeutics
NASDAQ: SABSMiami Beach, US · Founded 2020 · Delaware corporation
Founders & leadership
SAB Biotherapeutics was founded in 2020 by Eddie Sullivan and Eddie J Sullivan.
ES
Eddie SullivanCo-founder
EJ
Eddie J SullivaninFounderFounder and chief executive of SAB Biotherapeutics, a biotechnology company, with experience in areas including FDA regulation, life sciences, vaccines, laboratory work, and infectious diseases. He also has a background in business development and organizational development.
SR
Samuel ReichExecutive
RB
Russell BeyerExecutive
Board
JS
Jeffrey SpragensBoard director
AM
Andrew MoinBoard director
JS
Jay SkylerBoard director
EL
Erick LuceraBoard director
WP
William PolvinoBoard director
KE
Katie ElliasBoard director
DL
David LinkBoard director
SG
Scott GibersonBoard director
Reported raises · per SEC filings
Form D private placements$182.5M disclosed across 2 rounds · 2023–2025
▶$175MraisedAug 2025 · 17 investors · BiotechnologyRule 506(b)
▶$175MraisedAug 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MoinDirector
- Jay SkylerDirector
- Erick LuceraDirector
- Samuel ReichExecutive Officer, Director
- William PolvinoDirector
- Katie ElliasDirector
- Eddie SullivanExecutive Officer, Director
- Jeffrey SpragensDirector
- David LinkDirector
- Scott GibersonDirector
- Christine HamiltonDirector
- Offering amount
- $175M
- Amount sold
- $175M
- Sales commissions
- $10.5M
- Placement agents
- Oppenheimer & Co. Inc., Chardan Capital Markets, LLC, Leerink Partners LLC, UBS SECURITIES LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.5MraisedOct 2023 · 13 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Russell BeyerExecutive Officer
- Erick LuceraDirector
- David Charles LinkDirector
- Samuel ReichExecutive Officer, Director
- Eddie J. SullivanExecutive Officer, Director
- William PolvinoDirector
- Christine HamiltonDirector
- Scott GibersonDirector
- Andrew MoinDirector
- Jeffrey G. SpragensDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Sales commissions
- $450K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.4M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded SAB Biotherapeutics?
- SAB Biotherapeutics was founded by Eddie Sullivan, Eddie J Sullivan in 2020.
- How much funding has SAB Biotherapeutics raised?
- SAB Biotherapeutics has disclosed $182.5M raised across 2 rounds.
- Where is SAB Biotherapeutics headquartered?
- SAB Biotherapeutics is headquartered in Miami Beach, US.